2024
Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence
Xie Z, Komrokji R, Al Ali N, Smith A, Geyer S, Patel A, Saygin C, Zeidan A, Bewersdorf J, Mendez L, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg H, Ades L, Yi C, Osman A, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner A, Carraway H, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik M, Malcovati L, Savona M, Al-Kali A. Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence. Blood 2024 PMID: 38996210, DOI: 10.1182/blood.2024024756.Peer-Reviewed Original ResearchMyeloid neoplasmsIncidence of MNClonal cytopeniaCumulative incidencePlatelet count <High-risk mutationsCox proportional hazards modelsVariant allele fractionProportional hazards modelClinical trial designCCUS patientsStratify patientsGray's testC-indexDisease entityRisk groupsCytopeniasAllele fractionSomatic mutationsRisk factorsHigh riskNatural historyRisk scoreHazards modelPatients
2020
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?
Bewersdorf JP, Zeidan AM. Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? Best Practice & Research Clinical Haematology 2020, 33: 101222. PMID: 33279182, DOI: 10.1016/j.beha.2020.101222.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaRandomized clinical trialsMyelodysplastic syndromeClinical trialsCheckpoint inhibitorsMyeloid leukemiaRecent randomized clinical trialsRecent clinical trial dataEarly phase clinical trialsImmune checkpoint inhibitorsMultiple novel agentsClinical trial dataPhase clinical trialsClinical trial designSynergistic combination therapyImmunophenotypic biomarkersRandomized trialsCombination therapySolid malignanciesNovel agentsTrial designTrial dataNovel targetAvailable evidenceTrials